Clinical trial
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
NCT00263016 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00263016 |
|---|---|
| Title | Docetaxel in Non Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-Responsive Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Docetaxel |
| Enrollment | 50 |
| Start date | May 1, 2005 |
| First posted | Dec 7, 2005 |
| Last update posted | Mar 20, 2008 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: